- Home
- PAXS vs TRVI Comparison
PAXS vs TRVI Comparison
Compare PAXS & TRVI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PAXS
- TRVI
- Stock Information
- Founded
- PAXS 2021
- TRVI 2011
- Country
- PAXS United States
- TRVI United States
- Employees
- PAXS N/A
- TRVI N/A
- Industry
- PAXS Investment Managers
- TRVI Biotechnology: Pharmaceutical Preparations
- Sector
- PAXS Finance
- TRVI Health Care
- Exchange
- PAXS Nasdaq
- TRVI Nasdaq
- Market Cap
- PAXS 723.1M
- TRVI 725.7M
- IPO Year
- PAXS N/A
- TRVI 2019
- Fundamental
- Price
- PAXS $16.26
- TRVI $8.25
- Analyst Decision
- PAXS
- TRVI Strong Buy
- Analyst Count
- PAXS 0
- TRVI 9
- Target Price
- PAXS N/A
- TRVI $20.72
- AVG Volume (30 Days)
- PAXS 195.0K
- TRVI 2.9M
- Earning Date
- PAXS 01-01-0001
- TRVI 11-05-2025
- Dividend Yield
- PAXS 11.72%
- TRVI N/A
- EPS Growth
- PAXS N/A
- TRVI N/A
- EPS
- PAXS N/A
- TRVI N/A
- Revenue
- PAXS N/A
- TRVI N/A
- Revenue This Year
- PAXS N/A
- TRVI N/A
- Revenue Next Year
- PAXS N/A
- TRVI N/A
- P/E Ratio
- PAXS N/A
- TRVI N/A
- Revenue Growth
- PAXS N/A
- TRVI N/A
- 52 Week Low
- PAXS $12.57
- TRVI $2.36
- 52 Week High
- PAXS $15.93
- TRVI $9.92
- Technical
- Relative Strength Index (RSI)
- PAXS 70.54
- TRVI 55.08
- Support Level
- PAXS $15.46
- TRVI $6.93
- Resistance Level
- PAXS $16.46
- TRVI $9.92
- Average True Range (ATR)
- PAXS 0.10
- TRVI 0.75
- MACD
- PAXS 0.02
- TRVI 0.17
- Stochastic Oscillator
- PAXS 72.16
- TRVI 44.15
About PAXS PIMCO Access Income Fund of Beneficial Interest
PIMCO Access Income Fund is a non-diversified, limited-term, closed-end management investment company. The fund seeks current income as an objective and capital appreciation as a secondary objective. It achieves the investment objectives by utilizing a dynamic asset allocation among multiple sectors in the public and private credit markets, including corporate debt.
About TRVI Trevi Therapeutics Inc.
Trevi Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the development and commercialization of the investigational therapy Haduvio (oral nalbuphine ER) for the treatment of chronic cough in adults with idiopathic pulmonary fibrosis, or IPF, and other chronic cough indications, and for the treatment of prurigo nodularis. Haduvio is an oral extended-release formulation of nalbuphine.